Beam Therapeutics (BEAM)

Beam Therapeutics Stock Analysis & Ratings

BEAM Stock Chart & Stats

Day’s Range$31.58 - $35.86
52-Week Range$27.77 - $138.52
Previous Close$33.94
Average Volume (3M)1.16M
Market Cap$2.47B
P/E Ratio-9.8
Next EarningsAug 17, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)-3.61



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $27.77 and its highest was $138.52 in the past 12 months.
    What is Beam Therapeutics’s market cap?
    Beam Therapeutics’s market cap is $2.47B.
      What is Beam Therapeutics’s price target?
      The average price target for Beam Therapeutics is $91.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $127.00 ,the lowest forecast is $38.00. The average price target represents 160.50% Increase from the current price of $35.19.
        What do analysts say about Beam Therapeutics?
        Beam Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
          When is Beam Therapeutics’s upcoming earnings report date?
          Beam Therapeutics’s upcoming earnings report date is Aug 17, 2022 which is in 88 days.
            How were Beam Therapeutics’s earnings last quarter?
            Beam Therapeutics released its earnings results on May 09, 2022. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.892 by -$0.118.
              Is Beam Therapeutics overvalued?
              According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
                Does Beam Therapeutics pay dividends?
                Beam Therapeutics does not currently pay dividends.
                What is Beam Therapeutics’s EPS estimate?
                Beam Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Beam Therapeutics have?
                Beam Therapeutics has 70,270,000 shares outstanding.
                  What happened to Beam Therapeutics’s price movement after its last earnings report?
                  Beam Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.892. Following the earnings report the stock price went down -6.698%.
                    Which hedge fund is a major shareholder of Beam Therapeutics?
                    Among the largest hedge funds holding Beam Therapeutics’s share is ARK Investment Management LLC. It holds Beam Therapeutics’s shares valued at 470M.


                      Beam Therapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(160.50% Upside)
                      Moderate Buy
                      The Beam Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Beam Therapeutics

                      Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

                      Similar Stocks
                      Price & Change
                      Fortune Brands
                      Revolution Medicines
                      1Life Healthcare
                      Passage Bio

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis